| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 454,726 | 430,750 | 5.57 | ||
| Gross Profit (Loss) | 149,748 | 142,123 | 5.37 | ||
| Operational Profit (Loss) | 10,720 | 7,736 | 38.57 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 8,392 | 7,927 | 5.87 | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 8,177 | 8,356 | -2.14 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 146,317 | 138,141 | 5.92 | ||
| Profit (Loss) per Share | 0.88 | 0.83 | |||
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Sales: Almujtama Alraida Medical Company achieved a sales increase, recording a growth of 5.6% in 2025 compared to the previous year. This growth resulted in an increase of 24 million Saudi Riyals, bringing totalsales to 454.7 million Saudi Riyals, compared to 430.8 million Saudi Riyals in 2024. This is primarily attributed to the expansion of its pharmacy network and its commitment to providing competitive value to its customers. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | Net Profit: The company achieved a net profit of 8.4 million Saudi Riyals in 2025, representing 1.8% of sales, compared to 7.9 million Saudi Riyals in 2024, an increase of 464 thousand Saudi Riyals. This is attributed to the following reasons: - Gross Profit: The company recorded an increase in gross profit of 7.6 million Saudi Riyals, reaching 149.7 million Saudi Riyals in 2025 compared to 142.1 million Saudi Riyals in 2024. This is due to the company's ongoing and continuous investment strategy to support sales growth. - Operating Expenses: Operating expenses increased by 4.6 million Saudi Riyals compared to the previous year, due to the company supporting its investments, including new openings across the Kingdom. Additionally, there was an increase in finance charges of 1.2 million Saudi Riyals compared to the previous year, primarily including interest expense related to lease liabilities and interest on bank facilities, in order to support the growth in sales. Based on the above, net profit increased by 464 thousand Saudi Riyals compared to the previous year. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | None |
| Additional Information | Please review the attachment. |
| Attached Documents | Attached Documents |
